Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer

References

• Michalski JM, Purdy JA, Winter K, Roach M, III, Vijayakumar S, Sandler HM, . Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000;46:391–402.
   PubMed Web of Science ®Google Scholar
• Zhang M, Moiseenko V, Liu M, Craig T. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: Result of organ motion simulations. Phys Med Biol 2006;51:269–85.
   PubMed Web of Science ®Google Scholar
• Moman MR, van der Heide UA, Kotte AN, van Moorselaar RJ, Bol GH, Franken SP, . Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol Epub 2010 Mar 22.
   Google Scholar
• Carl J, Lund B, Larsen EH, Nielsen J. Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy. Radiother Oncol 2006;78:199–206.
   PubMed Web of Science ®Google Scholar
• Carl J, Nielsen J, Holmberg M, Hojkjaer LE, Fabrin K, Fisker RV. A new fiducial marker for image-guided radiotherapy of prostate cancer: Clinical experience. Acta Oncol 2008;47:1358–66.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–6.
   PubMed Web of Science ®Google Scholar
• Roach M, III, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
   PubMed Web of Science ®Google Scholar
• Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, . Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: Results of a prospective European prostate cancer detection study. J Urol 2001;166:856–60.
   PubMed Web of Science ®Google Scholar
• Igdem S, Akpinar H, Alco G, Agacayak F, Turkan S, Okkan S. Implantation of fiducial markers for image guidance in prostate radiotherapy: Patient-reported toxicity. Br J Radiol 2009;82:941–5.
   PubMedGoogle Scholar
• Langenhuijsen JF, van Lin EN, Kiemeney LA, van d, V, McColl GM, Visser AG, . Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: Complication rate and risk factors. Int J Radiat Oncol Biol Phys 2007;69:671–6.
   PubMedGoogle Scholar
• Henry AM, Wilkinson C, Wylie JP, Logue JP, Price P, Khoo VS. Trans-perineal implantation of radio-opaque treatment verification markers into the prostate: An assessment of procedure related morbidity, patient acceptability and accuracy. Radiother Oncol 2004;73:57–9.
   PubMedGoogle Scholar
• Perry MJ, Roodhouse AJ, Gidlow AB, Spicer TG, Ellis BW. Thermo-expandable intraprostatic stents in bladder outlet obstruction: An 8-year study. BJU Int 2002;90:216–23.
   PubMed Web of Science ®Google Scholar
• Thomas C, Keyes M, Liu M, Moravan V. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008;72:447–55.
   PubMedGoogle Scholar
• Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:1085–92.
   PubMed Web of Science ®Google Scholar
• Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, . No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: A prospective study. Int J Radiat Oncol Biol Phys Epub 2009 Oct 30.
   Google Scholar
• Sannazzari GL, Ragona R, Ruo Redda MG, Giglioli FR, Isolato G, Guarneri A. CT-MRI image fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer. Br J Radiol 2002;75:603–7.
   PubMed Web of Science ®Google Scholar
• Huisman HJ, Futterer JJ, van Lin EN, Welmers A, Scheenen TW, van Dalen JA, . Prostate cancer: Precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. Radiology 2005;236:311–7.
   PubMed Web of Science ®Google Scholar
• Nichol AM, Brock KK, Lockwood GA, Moseley DJ, Rosewall T, Warde PR, . A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers. Int J Radiat Oncol Biol Phys 2007;67:48–56.
   PubMed Web of Science ®Google Scholar
• Delouya G, Carrier JF, Beliveau-Nadeau D, Donath D, Taussky D. Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer. Radiother Oncol Epub 2010 Apr 6.
   PubMedGoogle Scholar
• Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, . Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475–87.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, . Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
   PubMed Web of Science ®Google Scholar
• Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, . Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–6.
   PubMed Web of Science ®Google Scholar
• Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, . Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294:1233–9.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, . Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
   PubMed Web of Science ®Google Scholar
• Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, . Image guided dose escalated prostate radiotherapy: Still room to improve. Radiat Oncol 2009;4:50.
   PubMed Web of Science ®Google Scholar
• Engels B, Soete G, Verellen D, Storme G. Conformal arc radiotherapy for prostate cancer: Increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys 2009;74:388–91.
   PubMed Web of Science ®Google Scholar